A Phase 2 interventional study of eptacog alfa (activated) and vatreptacog alfa (activated) in Congenital Bleeding Disorder, Haemophilia A and Haemophilia B, sponsored by Novo Nordisk A/S. Completed at 45 sites in 18 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-07.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 5th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
American Thrombosis and Hemostasis Network · Sites in United States
Ages 12–100
By country, each count listing its studies:
recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2007.
This study's enrollment of 51 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 24 across the 19 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
92 studies in Hemophilia A by Novo Nordisk A/S: 8 open now, 12 under way, 5 of them phase 3. Of 78 finished, 20 (26%) have results posted.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 26th largest by enrollment of the 59 interventional ones that give a count, is the only one that started in 2007, is one of 7 in phase 2, and was the 3rd registered.
Novo Nordisk A/S’s Hemophilia A studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 92 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe, Japan, and North and South America.
The aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor VII analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: vatreptacog alfa (activated)
Drug: vatreptacog alfa (activated)
Drug: vatreptacog alfa (activated)
Drug: vatreptacog alfa (activated)
Drug: vatreptacog alfa (activated)
Drug: eptacog alfa (activated)
90 mcg/kg, injected i.v.
5 mcg/kg, injected i.v.
10 mcg/kg, injected i.v.
20 mcg/kg, injected i.v.
40 mcg/kg, injected i.v.
80 mcg/kg, injected i.v.
Number of Adverse Events (AEs)
Adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.
Activated Recombinant Human Factor VII Analogue Activity in the Blood
Time frame: 0-24 hours after trial product administration
Prothrombin Time (PT)
The test measures the clotting time of plasma following the activation of tissue factor (TF also called thromboplastin) and calcium to hypocalcemic plasma. PT was provided in percent based on the measured PT in seconds and related/converted with the relevant standard curve. The percent value was derived based on the hyperbolic relation between PT (sec) and % PT activity.
Time frame: pre-dose - 12 hours after trial product administration
F1 + 2 (Prothrombin Fragments 1+2)
Thrombin and F1+2 are formed in equimolar quantities by the enzymatic cleavage of prothrombin (FII), and F1+2 thus indicate that thrombin has been generated.
Time frame: pre-dose - 12 hours after trial product administration
Activated Partial Thromboplastin Time (aPTT)
The aPTT time measured in clinical samples reflects both the effect of the drugs (generation of thrombin and FXa) and the presence of rFVIIa /rFVIIa analogue in the plasma samples causing a dose dependent shortening of the clotting time.
Time frame: pre-dose - 12 hours after trial product administration
Cessation of Bleeding: Number of Doses Needed to Control Bleeding
Time frame: Within 9 hours after first trial product administration or need of additional haemostatic medication within 9 hours after first trial administration additional haemostatic agents required to control bleed (treatment failure)
Number of Subjects With Need for Additional Haemostatic Agents
Time frame: within 24 hours after successful control of bleeding episode with trial product
Pharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) )
Time frame: 0-24 hours after trial product administration
Pharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity)
Time frame: 0-24 hours after trial product administration
Pharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time)
Time frame: 0-24 hours after trial product administration
Pharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life)
Time frame: 0-24 hours after trial product administration
Pharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance)
Time frame: 0-24 hours after trial product administration
Pharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State)
Time frame: 0-24 hours after trial product administration
Immunogenicity (Inhibitor Development)
Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or rFVIIa.
Time frame: Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.
Biochemistry: ALAT (Alanine Aminotransferase)
Time frame: screening visit, pre-dose and 12 hours after dosing
Biochemistry: Creatinine
Time frame: screening visit, pre-dose and 12 hours after dosing
Haematology: Haemoglobin
Time frame: screening visit, pre-dose and 12 hours after dosing
Haematology: Red Cell Count
Time frame: screening visit, pre-dose and 12 hours after dosing
Haematology: Packed Cell Volume
Time frame: screening visit, pre-dose and 12 hours after dosing
Haematology: White Cell Count
Time frame: screening visit, pre-dose and 12 hours after dosing
Haematology: Platelet Count
Time frame: screening visit, pre-dose and 12 hours after dosing
A total of 40 sites were initiated globally in 18 countries, including Argentina, Brazil, Canada, Croatia, France, Hungary, Israel, Italy, Japan, Malaysia, Poland, South Africa, Spain, Turkey, Taiwan, Thailand, the United Kingdom and the United States
| Milestone | All Subjects |
|---|---|
| Started | 51 |
| Completed | 42 |
| Not completed | 9 |
| Withdrew: Adverse event | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Physician decision | 2 |
Adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| events | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| All AEs | 10 | 8 | 5 | 5 | 0 | 11 |
| Serious AEs | 3 | 5 | 2 | 2 | 0 | 3 |
| IU/mL | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pre-dose | — | — | 0.1 ± 0.1 | 0.1 ± 0 | 0 ± 0 | 0.1 ± 0 |
| 1 hours post-dose | — | — | 5.3 ± 1.3 | 12.8 ± 5.3 | 19.7 ± 7.2 | 28.0 ± 12.6 |
| 12 hours post-dose | — | — | 0.4 ± 0.4 | 2.3 ± 4.5 | 0.3 ± 0.3 | 14.1 ± 27.3 |
| 24 hours post-dose | — | — | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0.1 ± 0 |
The test measures the clotting time of plasma following the activation of tissue factor (TF also called thromboplastin) and calcium to hypocalcemic plasma. PT was provided in percent based on the measured PT in seconds and related/converted with the relevant standard curve. The percent value was derived based on the hyperbolic relation between PT (sec) and % PT activity.
| percentage (%) | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pre-dose | 80.1 ± 12.6 | 77.6 ± 19.1 | 79.1 ± 14.9 | 85.9 ± 15.5 | 85.5 ± 8.8 | 88.3 ± 25.6 |
| 1 hours post-dose | 84.3 ± 16.3 | 99.6 ± 17.9 | 112.1 ± 14.6 | 123.4 ± 14.7 | 128.5 ± 7.6 | 139.0 ± 0 |
| 12 hours post-dose | 82.1 ± 16.2 | 73.2 ± 19.2 | 86.9 ± 14.1 | 94.5 ± 17.5 | 92.3 ± 16.8 | 112.1 ± 29.1 |
Thrombin and F1+2 are formed in equimolar quantities by the enzymatic cleavage of prothrombin (FII), and F1+2 thus indicate that thrombin has been generated.
| pmol/L | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pre-dose | 289.8 ± 310.9 | 131.8 ± 48.7 | 139.1 ± 50.4 | 121.2 ± 34.5 | 125.4 ± 45.9 | 169.3 ± 56.9 |
| 1 hour post-dose | 443.7 ± 414.7 | 241.7 ± 162.0 | 401.6 ± 292.6 | 365.9 ± 145.4 | 385.7 ± 88.8 | 309.7 ± 284.5 |
| 12 hour post-dose | 325.9 ± 299.4 | 198.9 ± 250.9 | 158.6 ± 54.5 | 199.8 ± 91.5 | 136.9 ± 43.8 | 268.2 ± 158.0 |
The aPTT time measured in clinical samples reflects both the effect of the drugs (generation of thrombin and FXa) and the presence of rFVIIa /rFVIIa analogue in the plasma samples causing a dose dependent shortening of the clotting time.
| Sec | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pre-dose | 120.6 ± 22.6 | 126.0 ± 26.4 | 122.8 ± 15.9 | 119.2 ± 31.3 | 117.4 ± 17.9 | 113.8 ± 17.4 |
| 1 hours post-dose | 102.1 ± 19.4 | 79.7 ± 13.9 | 68.7 ± 15.7 | 52.8 ± 14.1 | 48.6 ± 24.0 | 70.0 ± 9.8 |
| 12 hours post-dose | 111.7 ± 22.4 | 107.9 ± 27.7 | 107.9 ± 14.8 | 104.4 ± 31.2 | 99.3 ± 19.6 | 98.6 ± 20.8 |
| bleeding episodes | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| 1 dose | 3 | 3 | 2 | 5 | 4 | 6 |
| 2 doses | 5 | 9 | 7 | 6 | 4 | 4 |
| 3 doses | 4 | 4 | 7 | 4 | 2 | 7 |
| treatment failure | 3 | 3 | 0 | 1 | 0 | 2 |
| participants | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Number of Subjects With Need for Additional Haemostatic Agents | 4 | 1 | 1 | 1 | 1 | 1 |
| (IU*h)/mL | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) ) | — | — | 34.24 ± 27.00 | 66.85 ± 50.51 | 136.19 ± 18.56 | 74.35 ± 45.30 |
| (IU*h)/mL | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity) | — | — | 35.76 ± 26.34 | 71.23 ± 55.42 | 139.63 ± 18.35 | 101.38 ± 40.77 |
| hours | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time) | — | — | 0.68 ± 0.16 | 0.88 ± 0.33 | 0.56 ± 0.10 | 2.23 ± 0.54 |
| hours | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life) | — | — | 0.92 ± 0.18 | 1.28 ± 1.28 | 0.71 ± 0.16 | 1.66 ± 0.35 |
| mL/h | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance) | — | — | 9365.8 (6829.8 to 15065) | 11247 (5315.6 to 21314) | 10409 (6262.9 to 13276) | 3078.3 (1636.9 to 5039.4) |
| mL/kg | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Pharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State) | — | — | 5396.9 (3319.1 to 12215) | 9597.0 (5522.7 to 18310) | 5538.7 (4210.7 to 6482.6) | 6696.7 (3037.3 to 10328) |
Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or rFVIIa.
| participants | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Immunogenicity (Inhibitor Development) | 0 | 0 | 0 | 0 | 0 | 0 |
| U/L | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 26.0 ± 18.7 | 32.8 ± 31.3 | 30.6 ± 27.1 | 39.3 ± 33.3 | 24.2 ± 17.9 | 30.1 ± 21.4 |
| Pre-dose | 22.7 ± 19.9 | 29.9 ± 23.0 | 32.4 ± 37.1 | 29.1 ± 16.4 | 28.1 ± 16.6 | 49.4 ± 73.7 |
| 12 hours post-dose | 20.1 ± 16.8 | 25.6 ± 19.2 | 21.4 ± 15.4 | 30.9 ± 18.2 | 24.5 ± 14.4 | 45.1 ± 66.0 |
| micromol/L | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 66.9 ± 23.6 | 67.2 ± 13.8 | 63.6 ± 23.3 | 67.7 ± 15.7 | 60.0 ± 17.3 | 66.9 ± 16.0 |
| Pre-dose | 68.2 ± 23.3 | 70.1 ± 10.0 | 69.8 ± 15.3 | 69.1 ± 19.1 | 67.7 ± 10.8 | 71.1 ± 15.2 |
| 12 hours post-dose | 58.3 ± 23.6 | 63.1 ± 17.7 | 70.6 ± 16.8 | 71.9 ± 15.2 | 68.0 ± 10.7 | 70.6 ± 14.8 |
| g/dL | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 13.9 ± 1.8 | 14.7 ± 1.6 | 14.2 ± 1.4 | 14.2 ± 1.8 | 14.6 ± 1.3 | 13.8 ± 1.3 |
| Pre-dose | 13.8 ± 2.3 | 14.6 ± 1.7 | 14.4 ± 1.2 | 13.9 ± 2.1 | 14.8 ± 1.3 | 14.1 ± 1.3 |
| 12 hours post-dose | 13.5 ± 2.2 | 13.9 ± 1.7 | 13.7 ± 1.2 | 13.0 ± 2.2 | 14.2 ± 0.8 | 13.5 ± 1.3 |
| 10^12 cells/L | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 5.0 ± 0.5 | 5.4 ± 0.9 | 5.3 ± 1.0 | 5.1 ± 0.4 | 5.7 ± 1.2 | 5.3 ± 1.0 |
| Pre-dose | 5.1 ± 0.5 | 5.1 ± 0.4 | 5.2 ± 0.4 | 5.1 ± 0.4 | 5.1 ± 0.4 | 5.2 ± 0.5 |
| 12 hours post-dose | 5.0 ± 0.7 | 4.9 ± 0.4 | 4.9 ± 0.3 | 4.8 ± 0.5 | 4.9 ± 0.3 | 5.0 ± 0.6 |
| percentage (%) | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 41.6 ± 5.1 | 43.7 ± 3.9 | 42.2 ± 3.6 | 42.4 ± 4.3 | 44.0 ± 3.3 | 41.6 ± 3.8 |
| Pre-dose | 41.3 ± 6.1 | 43.1 ± 4.0 | 42.6 ± 3.2 | 42.5 ± 6.3 | 44.6 ± 4.6 | 42.3 ± 3.5 |
| 12 hours post-dose | 40.6 ± 6.0 | 40.9 ± 4.0 | 40.6 ± 2.9 | 39.9 ± 6.8 | 42.2 ± 2.9 | 40.4 ± 3.8 |
| 10^9 cells/L | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 6.7 ± 1.9 | 6.3 ± 2.5 | 7.2 ± 2.4 | 6.9 ± 2.7 | 6.6 ± 1.5 | 5.8 ± 1.8 |
| Pre-dose | 7.6 ± 2.3 | 7.3 ± 2.6 | 7.8 ± 1.9 | 7.1 ± 2.2 | 7.1 ± 2.3 | 6.5 ± 2.1 |
| 12 hours post-dose | 7.7 ± 3.4 | 7.2 ± 2.1 | 8.2 ± 2.0 | 7.3 ± 2.6 | 6.8 ± 1.4 | 7.1 ± 2.5 |
| 10^9 cells/L | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Screening | 259.8 ± 96.2 | 253.8 ± 82.9 | 250.8 ± 61.2 | 276.1 ± 75.5 | 272.5 ± 73.2 | 259.0 ± 86.1 |
| Pre-dose | 253.5 ± 90.5 | 248.6 ± 65.2 | 252.7 ± 50.8 | 278.8 ± 78.0 | 278.1 ± 59.0 | 271.1 ± 82.4 |
| 12 hours post-dose | 242.7 ± 83.7 | 244.8 ± 57.4 | 255.8 ± 61.9 | 287.0 ± 94.8 | 266.8 ± 53.1 | 260.7 ± 69.4 |
Collected over Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vatreptacog Alfa 5 mcg/kg | — | 2/16 (12.5%) | 6/16 (37.5%) |
| Vatreptacog Alfa 10 mcg/kg | — | 3/19 (15.8%) | 3/19 (15.8%) |
| Vatreptacog Alfa 20 mcg/kg | — | 2/16 (12.5%) | 3/16 (18.8%) |
| Vatreptacog Alfa 40 mcg/kg | — | 2/16 (12.5%) | 1/16 (6.3%) |
| Vatreptacog Alfa 80 mcg/kg | — | 0/10 (0%) | 0/10 (0%) |
| rFVIIa 90 mcg/kg | — | 2/19 (10.5%) | 8/19 (42.1%) |
| Event | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Colonic polypGastrointestinal disorders | 0/16 | 0/19 | 0/16 | 1/16 | 0/10 | 0/19 |
| Device dislocationGeneral disorders | 1/16 | 0/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/16 | 0/19 | 1/16 | 0/16 | 0/10 | 0/19 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/16 | 0/19 | 0/16 | 1/16 | 0/10 | 0/19 |
| Compartment syndromeMusculoskeletal and connective tissue disorders | 0/16 | 0/19 | 1/16 | 0/16 | 0/10 | 0/19 |
| HaematuriaRenal and urinary disorders | 1/16 | 0/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| AneurysmVascular disorders | 1/16 | 0/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| DyspepsiaGastrointestinal disorders | 0/16 | 1/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| CholecystitisHepatobiliary disorders | 0/16 | 1/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| Arthritis bacterialInfections and infestations | 0/16 | 0/19 | 0/16 | 0/16 | 0/10 | 1/19 |
| Event | Vatreptacog Alfa 5 mcg/kg | Vatreptacog Alfa 10 mcg/kg | Vatreptacog Alfa 20 mcg/kg | Vatreptacog Alfa 40 mcg/kg | Vatreptacog Alfa 80 mcg/kg | rFVIIa 90 mcg/kg |
|---|---|---|---|---|---|---|
| Incorrect dose administeredInjury, poisoning and procedural complications | 3/16 | 0/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 2/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| NauseaGastrointestinal disorders | 0/16 | 0/19 | 0/16 | 1/16 | 0/10 | 0/19 |
| Teeth brittleGastrointestinal disorders | 0/16 | 0/19 | 1/16 | 0/16 | 0/10 | 0/19 |
| Infusion site extravasationGeneral disorders | 0/16 | 0/19 | 1/16 | 0/16 | 0/10 | 0/19 |
| Injection site haematomaGeneral disorders | 1/16 | 0/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| Injection site haemorrhageGeneral disorders | 1/16 | 0/19 | 0/16 | 0/16 | 0/10 | 1/19 |
| NasopharyngitisInfections and infestations | 1/16 | 1/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| DizzinessNervous system disorders | 0/16 | 0/19 | 0/16 | 1/16 | 0/10 | 0/19 |
| HeadacheNervous system disorders | 1/16 | 0/19 | 0/16 | 0/16 | 0/10 | 0/19 |
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 28 ± 12.4 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 0 |
| Male | 51 |
The record gives a start of Jun 2007, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 4 years 6 months after primary completion. A results delay was requested in Nov 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Recombinant FVIIa · Vatreptacog alfa